Exploring the targeted delivery of biopharmaceutic.. (GlycoTarget)
Exploring the targeted delivery of biopharmaceuticals enabled by glycosylation control
Date du début: 1 mars 2014,
Date de fin: 28 févr. 2019
Most biotechnological therapeutics used in the clinic today and under current development, are of protein nature. Eukaryotic expression systems (such as yeasts and mammalian cells) for these therapeutic proteins add carbohydrate moieties (glycans) to the proteins, and these glycans strongly modulate the protein's in vivo biodistribution and therapeutic efficacy. Until recently, no adequate tools were available to accurately control glycosylation structure in these expression systems, but bio-engineering research in our lab and elsewhere has now largely overcome this problem.In the GlycoTarget ERC Consolidator grant project, we aim at exploring the relation between the structure of the glycans on therapeutic proteins and the in vivo targeting properties of these modified proteins to different tissues/cells/subcellular organelles.As highly medically relevant test cases for this exploration, we have selected three diseases with strong unmet therapeutic need, that could potentially be treated with glyco-targeted biopharmaceuticals through three different routes of protein delivery: progressive liver disease (intravenous), allergic asthma (subcutaneous immunization) and active tuberculosis (intrapulmonary delivery).
Bonjour, vous êtes sur la plateforme Région Sud Provence-Alpes-Côte d’Azur dédiée aux programmes thématiques et de coopération territoriale. Une équipe d’experts vous accompagne dans vos recherches de financements.
Contactez la Région Sud Provence-Alpes-Côte d'Azur
Vous pouvez nous écrire en Anglais, Français et Italien